3C Therapeutics
1 known investors
Find your way into 3C Therapeutics
364 people in our graph share verified history with the 3C Therapeutics team — schools, employers, funds. One of them is your warm intro.
Greg Rudinunlockedknows Dan Wattier · together at Creative Destruction Lab (overlapped)
×7knows the team · via Creative Destruction Lab
×3knows the team · via Centocor / Janssen Biotech
knows the team · via Genome British Columbia
3C Therapeutics develops therapeutics using targeted protein degradation, centered on a proprietary modular Degrader-Antibody Conjugate (DAC) platform (TriCore) that delivers intracellular protein degraders via monoclonal antibodies. The company focuses on drug discovery for previously inaccessible targets through a ligand-independent conjugation approach.
Founders & leadership
DP
David PerrinCo-Founder & Scientific Advisor
BN
Benjamin NoichlCo-Founder & VP of Chemistry
DW
Dan WattierinChief Executive OfficerHe has held executive roles at multiple biotech companies and has experience in R&D leadership, commercialization, and pharma-biotech partnerships.
TP
Tony PolverinoFractional CSO
DW
David WoodChief Financial Officer
Investors · 1
Frequently asked questions
- What does 3C Therapeutics do?
- 3C Therapeutics develops therapeutics using targeted protein degradation, centered on a proprietary modular Degrader-Antibody Conjugate (DAC) platform (TriCore) that delivers intracellular protein degraders via monoclonal antibodies. The company focuses on drug discovery for previously inaccessible targets through a ligand-independent conjugation approach.
- Who founded 3C Therapeutics?
- 3C Therapeutics was founded by David Perrin, Benjamin Noichl.
- Who are 3C Therapeutics's investors?
- 3C Therapeutics's investors include Innovation UBC.